We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Genflow Biosciences Plc | LSE:GENF | London | Ordinary Share | GB00BP2C3V08 | ORD GBP0.0003 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.08 | 5.26% | 1.60 | 305 | 08:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 1.50 | 1.70 | 1.60 | 1.60 | 1.60 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 169k | -1.63M | -0.0047 | -3.40 | 5.32M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 09:02:24 | O | 305 | 1.628 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 22/10/2024 | 10:49 | ALNC |  Genflow Biosciences secures EUR4 million for liver disease treatment |
| 22/10/2024 | 06:00 | UK RNS | Genflow Biosciences PLC Genflow Secures Non-Dilutive Financial Support |
| 30/9/2024 | 06:00 | UK RNS | Genflow Biosciences PLC Half-year Report |
| 27/6/2024 | 19:23 | ALNC | EARNINGS AND TRADING: Shuka Minerals loss narrows; Atome loss widens |
| 27/6/2024 | 12:30 | UK RNS | Genflow Biosciences PLC Result of AGM |
| 27/6/2024 | 06:00 | UK RNS | Genflow Biosciences PLC Strengthening of Pre-Clinical Efforts |
| 12/6/2024 | 15:41 | ALNC | EARNINGS AND TRADING: Distil loss widens; Genflow welcomes grant |
| 12/6/2024 | 06:00 | UK RNS | Genflow Biosciences PLC Receipt of Grant Funding |
| 03/6/2024 | 06:00 | UK RNS | Genflow Biosciences PLC Notice of AGM |
| 30/5/2024 | 11:03 | ALNC | Genflow Biosciences receives 50% of grant for sarcopenia project |
Genflow Biosciences (GENF) Share Charts1 Year Genflow Biosciences Chart |
|
1 Month Genflow Biosciences Chart |
Intraday Genflow Biosciences Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 05/12/2024 | 07:17 | Genflow Biosciences plc 2022 | 1,337 |
| 14/6/2023 | 17:08 | Old age a thing of the past? | 61 |
| 15/4/2022 | 10:31 | US SEC indicts key shareholder | - |
| 01/2/2022 | 11:45 | Welcome | 3 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 09:02:26 | 1.63 | 305 | 4.97 | O |
| 2024-12-10 16:35:07 | 1.52 | 27,037 | 410.96 | UT |
| 2024-12-10 15:48:38 | 1.60 | 35,157 | 562.16 | O |
| 2024-12-10 15:09:09 | 1.63 | 1,522 | 24.87 | O |
| 2024-12-10 14:11:39 | 1.56 | 6,483 | 100.81 | O |
| Top Posts |
|---|
Posted at 11/12/2024 08:20 by Genflow Biosciences Daily Update Genflow Biosciences Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker GENF. The last closing price for Genflow Biosciences was 1.52p.Genflow Biosciences currently has 349,706,618 shares in issue. The market capitalisation of Genflow Biosciences is £5,595,306. Genflow Biosciences has a price to earnings ratio (PE ratio) of -3.40. This morning GENF shares opened at 1.60p |
Posted at 03/12/2024 18:42 by moneymunch Genflow Biosciences (LON:GENF) (OTCQB:GENFF)1,782 followers 1h 🧬 The rise of exosome-based therapeutics has caused quite a stir in the #biotechnology field. 🧬 Earlier this year, BioSpace spotlighted the growing potential of the therapies. Recognized as a leader in the field, they turned to Genflow Biosciences (LON:GENF) (OTCQB:GENFF) CEO Dr. Eric Leire for his insights. 👀 Read what he had to say here: #GENF #GENFF Exosome Therapeutics Are Paving a Path to Clinical Readiness biospace.com |
Posted at 14/11/2024 07:14 by moneymunch Genflow Biosciences (LON:GENF) (OTCQB:GENFF)1,769 followers 18h With a growing population over 65, healthcare costs are climbing, making aging not just a societal challenge but a significant economic one. Genflow Biosciences (LON:GENF) (OTCQB:GENFF) is taking action to reduce this burden through focused research and innovation. #Genflow Highlights: ✅ Groundbreaking work on the #SIRT6 gene’s centenarian variant ✅ Development of new treatments addressing multiple health conditions ✅ A Scientific Advisory Board comprised of leading experts Discover our more about our work: #GENF #GENFF #aging |
Posted at 12/11/2024 15:23 by moneymunch Genflow Biosciences (LON:GENF) (OTCQB:GENFF)’Genflow Biosciences (LON:GENF) (OTCQB:GENFF) 1,767 followers 1d 🧬 Why Genflow Biosciences (LON:GENF) (OTCQB:GENFF)? 🧬 Genflow Biosciences offers investors a unique opportunity to support a #biotech company revolutionizing the #longevity field. Our innovative #SIRT6 work has led to recent attention, including being named "A Firm to Watch" by The Guardian. Learn more about #Genflow's investment story: #GENF #GENFF #invest #smallcap |
Posted at 22/10/2024 06:08 by moneymunch 22 October 2024Genflow Biosciences Plc Genflow Secures €4 Million Non-Dilutive Financial Support from Wallonia Region for GF-1002 Development Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased to announce today that it has received official confirmation of €4,026,525 in non-dilutive financial support from the Wallonia region. The funds will support the ongoing development of Genflow's lead gene therapy, GF-1002, for the treatment of Metabolic Associated Steatohepatitis (MASH), a severe and progressive liver disease. The financial support comprises a €1,218,349.44 non-reimbursable research grant, covering 70% of the Company's research costs, and a €2,808,175.92 recoverable advance, repayable to the Wallonia region upon commercialisation GF-1002 for use in treating MASH, funding 55% of the Company's development costs. This funding, when received, is expected to cover three years of Genflow's development program for GF-1002,with the first installment being received as working capital. The Company is committed to securing the necessary funding to cover its share of the project over the next three years. The securing of such funding marks a significant milestone for Genflow and will enable the Company to accelerate the clinical progress of GF-1002, which represents a novel approach to treating MASH, a condition with limited treatment options. The Wallonia region's financial support highlights the growing recognition of Genflow's innovative work in gene therapy. Dr. Eric Leire, CEO of Genflow, commented: "We are delighted to receive this substantial financial backing from the Wallonia region as it is an important validation of our research and development efforts. It will allow us to further the development of GF-1002 and strengthen our position at the forefront of gene therapy innovation for MASH treatment. We would like to sincerely thank the Wallonia region for its support." Further updates on the progress of GF-1002 will be provided in due course. |
Posted at 30/9/2024 06:04 by moneymunch PRESS RELEASE30 September 2024 Genflow Biosciences Plc ("Genflow" or "the Company") HALF YEAR RESULTS Genflow (LSE: GENF) is pleased to announce its half year results for the six-month period ended 30 June 2024. Chairman's Statement It is with pleasure that I take this opportunity to update shareholders of Genflow Biosciences Plc ("Genflow" or the "Company") on the Company's performance during the first six months of 2024. Over the six months to 30 June 2024, the Company has made strides in its principal longevity programs: MASH (Metabolic Dysfunction-Associat In June, we updated shareholders on the momentum created with respect to our pre-clinical programs in MASH, and the guidance expected to be received from the FDA in the future. This guidance, which we anticipate receiving in the future, is expected to come through the FDA's Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT), as a result of the Company submitting a comprehensive briefing package conducted with our lead drug candidate, GF-1002, for the treatment of MASH. In the meantime, the FDA has encouraged Genflow to proceed with its plans to identify appropriate animal models through pilot proof-of-concept ("POC") studies. Specifically, we have established a functional 3-D organoids of liver using cells from Werner patients. This organoid testing helps reduce the need for animal models in our scientific research. Organoids are miniature, lab-grown versions of human organs or tissues that mimic the structure and function of their real counterparts. By using these organoids, we can model human Werner Syndrome and better test response of our SIRT6 based gene therapy in a more human-relevant environment, rather than relying on unreliable animal models. Additionally, we have initiated a feasibility study with a Contract Development Manufacturing Organization (CDMO), Exothera S.A, to assess the ability to produce its future MASH clinical lot in accordance with Good Manufacturing Practices (GMP). We are also in the process of selecting Contract Research Organizations (CROs) to conduct our upcoming dog clinical trial, aimed at studying our simplified Nake DNA version of our Centenarian SIRT6 drug candidate, GF-1004. We will provide updates in relation to our veterinary study in due course. Over the period, we have also been working on two exciting collaborations supported by non-diluting and non-reimbursable research grants from the Government of Wallonia in Belgium, as follows; · Sarcopenia research program with Revatis SA - focusing on the development of muscle progenitor cells which will be loaded with Genflow's proprietary SIRT6 for the prevention and treatment of sarcopenia, the age-related loss of muscle mass and function. Genflow aims to counteract the detrimental effects of aging on muscle tissue with our sarcopenia program, which holds potential for significantly improving the quality of life for older adults affected by muscle loss and weakness. · Exosome-mRNA project with EXO Biologics - which aims to deliver a therapeutic product composed of exosomes encapsulating an AAV or mRNA encoding SIRT6. The exosome therapy will be designed to target liver fibrosis (MASH) and Werner Syndrome, potentially leading to groundbreaking treatments for both diseases. During the period, the Company has received grant funding of totalling €777,281 in respect of these projects, with further financial support committed in the first half of 2025. In addition, Genflow Biosciences SRL, received €350,000 in April 2024, from the regional government of Wallonia - Belgium Service Public de Wallonie, representing the second tranche of this awarded grant recognised in the previous year, 2023. Further strengthening the Company's financial position and increasing its institutional investor base, the Company completed a placing and subscription to which raised £715,000 (before expenses) during the period. We were privileged to have Premier Miton, a well-known UK institution, participate in this fundraise. Financial Overview As of 30 June 2024, the Group had cash reserves of £1,139,859 (31 December 2023: £683,974) which has been derived from equity fundraising of £663,600 (net of expenses) and the receipt of research and development grants of £664,219 (€777,281) and £299,145 (€350,000) The Company remains debt free. Administration expenses for 30 June 2024 totalled £1,316,368 (30 June 2023: £815,477), which primarily consisted of research and development costs of £938,109 (30 June 2023: £415,157), legal and professional fees totalling £90,654 (30 June 2023: £103,366) and Directors' fees of £178,656 (30 June 2023: £178,783). The significant jump in research and development costs for 2024 is in relation to the advancement of testing, which has transitioned to the in vivo stage, which is inherently more costly. Other Comprehensive Income was charged with a translation gain of £8,652 upon converting the Subsidiary's results for the period to GBP. Future On behalf of the Board, I thank you for your continued support. Our commitment to pioneering therapeutic solutions for longevity has been strengthened by the support of our collaborative partners and promising feedback from the FDA during the six-months to 30 June 2024. This encouragement reinforces our commitment to developing effective therapeutic solutions for age-related diseases. We remain focused on our mission to improve healthspan, and I look forward to providing you with further updates as we progress through our work programs, including clinical dog trials. |
Posted at 17/9/2024 06:15 by moneymunch Genflow Biosciences Plc to Present at the Life Sciences Investor Forum September 19thCompany invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConfe September 16, 2024 08:57 ET | Source: Virtual Investor Conferences Share LONDON, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Genflow Biosciences Plc (LSE:GENF OTCQB:GENFF), based in the UK, focused on pioneering gene therapies to decelerate the aging process, today announced that Dr Eric Leire, Chief Executive Officer, will present live at the Life Sciences Investor Forum, hosted by VirtualInvestorConfe DATE: September 19th TIME: 10:00 AM ET LINK:https ://bit.ly/3XjDJkL Available for 1x1 meetings: September 19 This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates. Learn more about the event at www.virtualinvestorc About Genflow Biosciences Plc Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional and social impacts of a fast-growing aging global population. Genflow’s lead compound, GF-1002, works through the delivery of a centenarian variant of SIRT6 gene which has yielded promising preclinical results. Scheduled to begin in 2025, Genflow’s clinical trial aims to explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associat |
Posted at 29/8/2024 15:10 by moneymunch Genflow Biosciences (LON:GENF) (OTCQB:GENFF)’Genflow Biosciences (LON:GENF) (OTCQB:GENFF) 1,709 followers 3h Genflow Biosciences (LON:GENF) (OTCQB:GENFF)'s poster presentation at the 11th Annual Aging Research and Drug Discovery Meeting has been a standout success! The company is showcasing its groundbreaking #SIRT6 research, which is sparking significant interest at the conference. Stay tuned for more updates! #biotech #aging #GENF #GENFF |
Posted at 21/8/2024 17:28 by moneymunch Genflow Biosciences (LON:GENF) (OTCQB:GENFF)1,701 followers 5h 🧬 Exciting news from Genflow Biosciences (LON:GENF) (OTCQB:GENFF)! Next week, #Genflow will share the company's latest revolutionary #SIRT6 work at the 11th Annual Aging Research & Drug Discovery Meeting . Learn more about #GENF's groundbreaking work: #GENF #GENFF #MASH #longevity #healthspan |
Posted at 13/6/2023 06:02 by moneymunch RNS Number : 4646CGenflow Biosciences PLC 13 June 2023 Genflow Biosciences Plc ("Genflow" or "the Company") Anti-Ageing Company, Genflow Biosciences, Announces Listing on OTCQB Venture Market in addition to its LSE Main Market Listing Genflow has 3 Gene Therapies in Development Seeking to Treat NASH and Werner Syndrome Genflow Biosciences Plc ("Genflow" or "the Company") is pleased to announce that, after a successful application process, its Ordinary Shares ("Ordinary Shares") begin trading on the OTCQB Venture Market in the United States ("US") today under the symbol GENFF. Genflow will continue to trade on the London Stock Exchange ("LSE") Main Market under the symbol GENF, and, importantly, the onboarding to this additional U.S. securities trading platform does not involve any capital raise. The new U.S. trading facility expands access to a broader pool of investors and enables investors in the United States to trade during U.S. trading hours and in U.S. dollars. Eric Leire, CEO of Genflow, expressed his excitement about this significant achievement, stating, "We are thrilled to announce that Genflow Biosciences has been admitted to trading on the OTCQB Venture Market in the United States. This move not only expands our reach to a larger investor base and has the potential to enhance liquidity for our shares, but also reinforces our unwavering commitment to our primary listing on the prestigious London Stock Exchange." Tamara Joseph, Chair of the Board, also expressed her enthusiasm on behalf of the Board of Directors, saying, "Genflow is developing gene therapies that could address an important source of many global illnesses: aging. As the Company moves into Phase I/II clinical trials to treat potentially the orphan condition Werner Syndrome, which causes premature aging, and NASH, a liver disease that affects an estimated 35 million people around the world, it is the right time to retain our London Stock Exchange listing while adding easier access for US investors." Further information on Genflow's application and the OTCQB market is below: As a Foreign Private Issuer, Genflow's admission to the OTC Markets is subject to meeting the requirements for OTCQB, which apply to international reporting companies. This includes fulfilling the criteria for exemption under the US Exchange Act Rule 12g3-2(b) from SEC reporting. The Rule 12g3-2(b) exemption includes the disclosure obligation to ensure that certain information made public or distributed under home market regulations is made publicly available on the Company's website or other electronic information delivery system in English. Thus, the Company will have no additional reporting obligations and incur minimal ongoing costs; admission to the OTC Markets is subject to meeting the requirements for OTCQB, which apply to international reporting companies. This includes fulfilling the criteria for exemption under the US Exchange Act Rule 12g3-2(b) from SEC reporting. Under this exemption, the Company must ensure that information made public or distributed under its home market regulations is made available to the public on its website or another electronic information delivery system in English. Consequently, Genflow will have no additional reporting obligations and will incur minimal ongoing costs compared to traditional major exchanges. As a verified market, the OTCQB offers transparent trading for companies that have met a minimum bid price test, are current in their financial reporting and have undergone an annual verification and management certification process. The cross-trading facility is provided through OTC Markets Group Inc., located in New York. OTC Markets operates the world's largest electronic interdealer quotation system for US broker-dealers and offers multiple media channels to increase the visibility of OTC-listed companies. Online brokers such as Ameritrade, Fidelity Investments, Tradestation, Charles Schwab and E-trade all offer OTCQB trades. US investors can find real-time quotes, market information and access current company news and developments on a BSF page on the OTC Markets website at www.otcmarkets.com. Genflow appointed the corporate securities law firm Galanopoulos & Company as its OTCQB Sponsor to support its onboarding to the OTCQB Venture Market. Additional information about the OTCQB market can be found at: www.otcmarkets.com/l The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014. |
Posted at 06/6/2023 18:06 by stark industries Here's why this UK BioTech stock could potentially be set to rise imminentlyToday I’m going to tell you about a revolutionary biotech startup that I previously tipped when it was trading at 2p back in November. A company I believe is set to explode and has the potential to rise significantly in the near term. What justifies such a bold prediction? This company may hold the keys to the cure for aging... The name of the company is Genflow Biosciences and it trades under the ticker (GENF) on the London stock exchange. Consider that the biotech market is expected to reach USD 2.44 trillion by 2028 and expand at a CAGR of 15.83% until then.* The demand for longevity is limitless, and the first companies that succeed in supplying the disruptive technologies that unlock it will capture the lion’s share of those trillions. But before I go any further, let me ask you something… Have you heard of the freshly minted biotech mega-startup that received $3 billion in backing in a single day? According to Forbes, Altos Labs likely holds the world record for financing of any start-up by an order of magnitude or more. With reports of early investments from entrepreneurial juggernaut Jeff Bezos and renowned info-tech investor Yuri Milner, Altos Labs is a likely contender for a top spot in the race to reverse aging and revolutionize medicine. But backing from big names isn’t the only ace up the sleeve of Altos Labs… The company has built an executive dream team of industry experts and scientific luminaries. Among those reported to be joining the ambitious roster is none other than the Nobel prize winner for the discovery of reprogramming. What is reprogramming and why is it important you might ask? Shinya Yamanaka won his Nobel prize for discovering how to transform ordinary adult skin cells into any cell in the human body. Need a new liver? Tired of living with Parkinson’s? Want your eyesight back? Yamanaka’s research is key to engineering the regenerative medicine that will one day be responsible for replacing and repairing damaged organs and tissues. With a deluge of capital and a hot shot team to employ it efficiently, Altos Labs is poised to accomplish its mission statement, “to restore cell health and resilience to reverse disease, injury, and disabilities that occur throughout life.” But what does all of this have to do with Genflow Biosciences potentially significant rise in value? I’m going to tell you, but first, let’s get some background. Genflow Biosciences is challenging the aging process with exclusive patents to the leading longevity technology from the University of Rochester (US). Okay, but why should we expect such sudden exponential growth. The answer lies in a 2013 paper published in a highly regarded journal entitled “The Hallmarks of Ageing”... To put it simply, the paper outlines 9 hallmarks of aging that provide a framework for prolonging human life. This roadmap to longevity spawned numerous biotech companies that used it as a roadmap for their R&D. But even the companies regarded as the cream-of-crop are at a disadvantage… They tend to focus on a single hallmark of aging. To quote Eric Leire, the company’s chief executive, “You’ve only solved one-ninth of the problem with this approach.” Genflow Biosciences takes a holistic approach by targeting 4 of the 9 hallmarks directly, in addition to 2 indirectly. They are able to do this by focusing on the SIRT6 gene. This gene’s over expression has proven to extend the lives of healthy mice, winning it the title of the “master regulator of aging”. This novel research has allowed the company to capture alluring patents, which brings us back to Altos Labs… If anyone wants this IP they would have to purchase the company at a significant premium to the current share price or enter a licensing agreement. Altos Labs opened only last year, in January of 2022. We know that Altos Labs has the ambition and the means to become the leader in longevity tech, and Genflow Biosciences likely holds the keys to that ambition. It stands to reason that Genflow Biosciences could become an attractive acquisition target for a mega-tech startup such as Altos Labs. Markets are extremely sensitive to takeovers, and the mere rumour of a potential acquisition could result in a drastic increase in Genflow's significantly undervalued share price News like this could pop at any second. Launching Genflow Biosciences into the spotlight at any time this year. This is a highly competitive industry and players with deep pockets see Genflow Biosciences’ IP as their ticket to the top of the market. If it’s not Altos Labs, then surely there will be another. That is why I am recommending readers take a close look at it right now. The company is currently eyeing a listing in other markets and a US listing may be on the horizon. If I were to bet on the next big biotech stock story, Genflow BioSciences would be it. Altos Labs opened only last year, in January of 2022. We know that Altos Labs has the ambition and the means to become the leader in longevity tech, and Genflow Biosciences likely holds the keys to that ambition. It stands to reason that Genflow Biosciences could become an attractive acquisition target for a mega-tech startup such as Altos Labs. Markets are extremely sensitive to takeovers, and the mere rumour of a potential acquisition could result in a drastic increase in Genflow's significantly undervalued share price I suggest you all read through the attached link. Mind Blowing as to how low our MCap is compared to our U.S neighbours Target was 16p upon IPO and now with all the latest positives and the announcement of the U.S listing......expecti conservative X 10 Share Price from current position !!! |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
